Etid klinik pou Lupus nan Illinois
14 etid pou Lupus ap chèche patisipan nan sit nan Illinois.
Vil nan Illinois
Tèks ofisyèl etid la (Anglè)
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Research Site, Chicago
- Research Site, Chicago
Ap rekriteFaz 3
Laj 5 a 17 · Tout sèks · Mizajou Sep 30, 2026 · NCT05835310A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Willow Rheumatology and Wellness PLLC, Willowbrook
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07438496A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 279147, Orland Park
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07607964A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Willowbrook
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 25, 2026 · NCT07430306A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- University of Chicago, Chicago
Ap rekriteFaz 2
Laj 16 a 70 · Tout sèks · Mizajou Sep 17, 2026 · NCT07328581A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Research Site, Chicago
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Sep 10, 2026 · NCT06897930A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- The University of Chicago Medical Center, Chicago
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50699, Chicago
- Sl0044 50717, Willowbrook
Ap rekriteFaz 3
Laj 16 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06617325A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Willow Rheumatology & Wellness, Willowbrook
Ap rekriteEtid obsèvasyon
Laj 16 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07175285A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Aug 28, 2026 · NCT06925542RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Aug 26, 2026 · NCT06121297A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
- Advanced Quality Medical Research /ID# 278462, Orland Park
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Aug 10, 2026 · NCT06977724Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Robert A Hozman MD SC, Skokie
- Willow Rheumatology Wellness, Willowbrook
Ap rekriteFaz 3
Laj 12 a 100 · Tout sèks · Mizajou Jul 8, 2026 · NCT06133972Lupus Landmark Study: A Prospective Registry and Biorepository
- University of Chicago, Chicago
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Apr 15, 2026 · NCT05934149Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.